Budesonide capsules, 3mg
Crohn's Disease
ApprovedActive
Key Facts
About Sciecure Pharma
Sciecure Pharma is a private, commercial-stage generic drug company that has successfully navigated the FDA approval pathway for at least two products since its founding in 2015. The company operates in the highly competitive but essential generic pharmaceuticals sector, aiming to offer lower-cost alternatives to branded medications. Its approved products include a generic version of Paroxetine HCl Extended Release tablets and Budesonide capsules, indicating a focus on central nervous system and gastrointestinal/inflammatory conditions. As a small, private entity, its growth will depend on its ability to expand its portfolio through additional ANDA filings and approvals.
View full company profileTherapeutic Areas
Other Crohn's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| PALI-2108 | Palisade Bio | Preclinical |
| TRX319 | Tr1X | Phase 1/2a |
| Program not named | Reponex | Pre-clinical |
| EXL01 | Exeliom Biosciences | Phase 2 |
| CVT12011965 | CVasThera | Pre-clinical |
| StroMel™ (Planned) | Akan Biosciences | Planned |
| omilancor | NImmune Biopharma | Phase 2 |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 2/3 |
| VTX002 | Ventyx Biosciences | Phase 2 |